Myasthenia gravis

  title={Myasthenia gravis},
  author={Jennifer E. Spillane and Elizabeth Higham and Dimitri Michael Kullmann},
  journal={BMJ : British Medical Journal},
This is one of a series of occasional articles highlighting conditions that may be more common than many doctors realise or may be missed at first presentation. The series advisers are Anthony Harnden, university lecturer in general practice, Department of Primary Health Care, University of Oxford, and Richard Lehman, general practitioner, Banbury. To suggest a topic for this series, please email us at 

Topics from this paper

Paper Mentions

Blog Post
[Myasthenic Crisis].
Special demands in ICU treatments are a structured weaning concept, consequent treatment of comorbidities and complications, first and foremost infections, dysphagia management, and comprehensive prevention and treatments of delirium. Expand
Clinical Evaluation of Blepharoptosis: Distinguishing Age‐Related Ptosis from Masquerade Conditions: Oculofacial Plastic and Reconstructive Surgery
It is particularly important for the clinician to rule out neurologic causes of ptosis such as dysfunction of the third cranial nerve, Horner's syndrome, and myasthenia gravis, as these conditions can be associated with significant systemic morbidity and mortality. Expand
Epidemiological evidence for a hereditary contribution to myasthenia gravis: a retrospective cohort study of patients from North America
A genetic contribution to the pathogenesis of myasthenia gravis is suggested, as a high proportion of patients had a personal or family history of autoimmune disease. Expand
Thymic carcinoma patients with myasthenia gravis exhibit better prognoses
The OS of patients with thymic carcinoma depends on complete resection, but patients with Myasthenia gravis also demonstrate improved prognoses, which may account for their better prognose. Expand
Comparison of CT and chemical-shift MRI for differentiating thymoma from non-thymomatous conditions in myasthenia gravis: value of qualitative and quantitative assessment.
Quantitative analysis is useful in evaluating patients with MG and improves the diagnostic accuracy of CT and MRI based on qualitative assessment, and Chemical-shift MRI is more reliable than CT in differentiating THYs from non-thymomatous conditions. Expand
Features of depression development in myasthenia gravis.
A reliable correlation relationship was established between the quantitative evaluation of the severity of myasthenia gravis (according to the QMG score) and the results of the evaluation according to the BDI score in the total sample. Expand
Myastenia gravis li hastada KOAH alevlenmesine bağlı solunum yetmezliğinde yoğun bakım takibi
Miyastenia gravis (MG), iskelet kaslarinda gucsuzluk ve cabuk yorulma ile karakterize nikotinik asetilkolin reseptorlerinin otoimmun yikimi sonucu gelisen bir kas hastaligidir (1). Kas gucsuzlugu enExpand
A Rare Cause of Acute Respiratory Failure: Myasthenic Crisis
Miyastenia gravis, iskelet kaslarında güçsüzlük ve çabuk yorulma ile karakterize bir kas hastalığıdır. Miyastenik hastalarda çeşitli nedenlerle miyastenik kriz gelişebilir. Bu olgu sunumunda solunumExpand
Roles of collagen Q in MuSK antibody-positive myasthenia gravis.
It is proposed that attenuation of AChR clustering in Mu SK-MG is due to hindrance of LRP4-MuSK interaction in the presence of agrin by MuSK-IgG, and unexpectedly observed that both MuSK and ColQ suppressed agrin/LRP4/MuSK signaling in dose-dependent manners. Expand
Myasthénie auto-immune, prise en charge et traitement
Although considered as rare, generalized autoimmune myasthenia (GM) is the most frequent neuromuscular junction disease and immunomodulatory therapies including intravenous immunoglobulins and plasma exchanges have been shown efficient to reverse the course of GMcrisis. Expand


Myasthenia gravis: diagnostic and management dilemmas
This review focuses on the diagnostic tests that may help to confirm myasthenia in patients without acetylcholine receptor antibodies, including the newly discovered anti-muscle-specific receptorExpand
Myasthenia gravis: a population based epidemiological study in Cambridgeshire, England
This, the second highest reported prevalence for myasthenia, is likely to be the result of optimum case ascertainment, increased disease duration, application of complex diagnostic tests, and the impact of an aging population leading to a relative increase in the prevalence of ocular myastsia. Expand
Lifetime course of myasthenia gravis
The clinical course of MG was significantly influenced by age and gender, and these need special attention in managing patients, and novel drugs need to be developed to increase the number as well as normal functioning of the AChRs and other components of the neuromuscular system. Expand
Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients
Abstract One hundred consecutive patients with myasthenia gravis (MG) referred between 1985 and 1989 were analysed for epidemiological characteristics, evolution of early signs, delay in diagnosis,Expand
Myasthenia Gravis: A Review of Available Treatment Approaches
Patients with autoimmune myasthenia gravis (MG) should be further classified before initiating therapy, as treatment response varies for ocular versus generalised, early onset versus late onset, andExpand
The Epidemiology of Myasthenia Gravis
The age and ethnic distributions in the United States are evolving from those that were present when the majority of population‐based studies were done, and the distribution of severity of the disease may also have changed, so future studies of the epidemiology of MG should take these factors into account. Expand
Myasthenia Gravis in the Elderly
  • J. Aarli
  • Medicine
  • Annals of the New York Academy of Sciences
  • 2008
It is shown that myasthenia gravis in the elderly is diagnosed more often today than previously, and the increase is mainly found in patients over the age of 50 years, which means Neurologists therefore see more old patients with MG now than before. Expand
Evidence of underdiagnosis of myasthenia gravis in older people
The sharp fall in the incidence of clinically recognised myasthenia gravis in people over 80 years of age in the authors' national AChR antibody incidence study, and the high prevalence of previously unrecognised positive AchR antibodies in those ≥ 75 years old, suggest that myastshenia Gravis may be substantially underdiagnosed in older people. Expand
Myasthenia mimicking vertebrobasilar stroke
This work presents two cases of myasthenia presenting as posterior circulation stroke, and in one case, the tempo suggested basilar thrombosis. Expand
Myasthenic crisis: Guidelines for prevention and treatment
In the experience and based on a review of recent literature, the use of plasma exchange (PE) as a primary modality in the acute care setting, supported by other immunomodulatory medications such as corticosteroids is advocated. Expand